SMS Pharmaceuticals Limited

NSEI:SMSPHARMA Stock Report

Market Cap: ₹17.3b

SMS Pharmaceuticals Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for SMS Pharmaceuticals.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth18.8%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) 25% Share Price Surge Not Quite Adding Up

Feb 29
SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) 25% Share Price Surge Not Quite Adding Up

SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment

Sep 24
SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment

SMS Pharmaceuticals' (NSE:SMSPHARMA) Dividend Will Be ₹0.30

Sep 11
SMS Pharmaceuticals' (NSE:SMSPHARMA) Dividend Will Be ₹0.30

SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30

Aug 28
SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30

SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Somewhat Strained Balance Sheet

Jun 07
SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Somewhat Strained Balance Sheet

Shareholders May Not Be So Generous With SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation And Here's Why

Sep 23
Shareholders May Not Be So Generous With SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation And Here's Why

SMS Pharmaceuticals (NSE:SMSPHARMA) Is Due To Pay A Dividend Of ₹0.30

Sep 15
SMS Pharmaceuticals (NSE:SMSPHARMA) Is Due To Pay A Dividend Of ₹0.30

SMS Pharmaceuticals (NSE:SMSPHARMA) Will Pay A Dividend Of ₹0.30

Sep 01
SMS Pharmaceuticals (NSE:SMSPHARMA) Will Pay A Dividend Of ₹0.30

SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30

Aug 18
SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30

We Think SMS Pharmaceuticals (NSE:SMSPHARMA) Can Stay On Top Of Its Debt

Mar 22
We Think SMS Pharmaceuticals (NSE:SMSPHARMA) Can Stay On Top Of Its Debt

SMS Pharmaceuticals' (NSE:SMSPHARMA) Earnings Are Of Questionable Quality

Jun 03
SMS Pharmaceuticals' (NSE:SMSPHARMA) Earnings Are Of Questionable Quality

Should You Be Adding SMS Pharmaceuticals (NSE:SMSPHARMA) To Your Watchlist Today?

Mar 08
Should You Be Adding SMS Pharmaceuticals (NSE:SMSPHARMA) To Your Watchlist Today?

What Type Of Shareholders Make Up SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Share Registry?

Feb 22
What Type Of Shareholders Make Up SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Share Registry?

The SMS Pharmaceuticals (NSE:SMSPHARMA) Share Price Is Up 185% And Shareholders Are Boasting About It

Feb 08
The SMS Pharmaceuticals (NSE:SMSPHARMA) Share Price Is Up 185% And Shareholders Are Boasting About It

SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?

Jan 18
SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?

Here's Why SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Meaningful Debt Burden

Dec 09
Here's Why SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Meaningful Debt Burden

Should You Take Comfort From Insider Transactions At SMS Pharmaceuticals Limited (NSE:SMSPHARMA)?

Nov 18
Should You Take Comfort From Insider Transactions At SMS Pharmaceuticals Limited (NSE:SMSPHARMA)?

The SMS Pharmaceuticals (NSE:SMSPHARMA) Share Price Is Up 110% And Shareholders Are Boasting About It

Oct 28
The SMS Pharmaceuticals (NSE:SMSPHARMA) Share Price Is Up 110% And Shareholders Are Boasting About It

What Kind Of Shareholders Hold The Majority In SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Shares?

Oct 08
What Kind Of Shareholders Hold The Majority In SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Shares?

Are Dividend Investors Getting More Than They Bargained For With SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Dividend?

Sep 17
Are Dividend Investors Getting More Than They Bargained For With SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Dividend?

SMS Pharmaceuticals Limited (NSE:SMSPHARMA) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?

Aug 26
SMS Pharmaceuticals Limited (NSE:SMSPHARMA) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?

SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Share Price Could Signal Some Risk

Aug 08
SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Share Price Could Signal Some Risk

SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Business Is Trailing The Market But Its Shares Aren't

Aug 08
SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Business Is Trailing The Market But Its Shares Aren't

SMS Pharmaceuticals Limited (NSE:SMSPHARMA) Looks Just Right

Jul 25
SMS Pharmaceuticals Limited (NSE:SMSPHARMA) Looks Just Right

SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Share Price Matching Investor Opinion

Jul 07
SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Share Price Matching Investor Opinion

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as SMS Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NSEI:SMSPHARMA - Analysts future estimates and past financials data (INR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20236,129361N/AN/AN/A
9/30/20236,002288343751N/A
6/30/20235,930150N/AN/AN/A
3/31/20235,221-71-75225N/A
12/31/20224,335-42N/AN/AN/A
9/30/20224,0609-221-49N/A
6/30/20224,211259N/AN/AN/A
3/31/20225,199622178451N/A
12/31/20216,348789N/AN/AN/A
9/30/20216,612911-325815N/A
6/30/20216,172791N/AN/AN/A
3/31/20215,632625-613905N/A
12/31/20204,911458N/AN/AN/A
9/30/20204,226319-239482N/A
6/30/20204,130308N/AN/AN/A
3/31/20204,143316-30397N/A
12/31/20194,206386N/AN/AN/A
9/30/20194,412405-149330N/A
6/30/20194,606406N/AN/AN/A
3/31/20194,667400149498N/A
3/31/20184,639317233318N/A
3/31/20174,388285N/A735N/A
3/31/20166,032409N/A612N/A
12/31/20155,902391N/AN/AN/A
9/30/20155,828396N/AN/AN/A
6/30/20155,651343N/AN/AN/A
3/31/20155,793352N/A789N/A
12/31/20145,730358N/AN/AN/A
9/30/20145,624327N/AN/AN/A
6/30/20145,567326N/AN/AN/A
3/31/20145,180204N/A651N/A
12/31/20133,976686N/AN/AN/A
9/30/20133,396430N/AN/AN/A
6/30/20132,771-792N/AN/AN/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if SMSPHARMA's forecast earnings growth is above the savings rate (6.7%).

Earnings vs Market: Insufficient data to determine if SMSPHARMA's earnings are forecast to grow faster than the Indian market

High Growth Earnings: Insufficient data to determine if SMSPHARMA's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if SMSPHARMA's revenue is forecast to grow faster than the Indian market.

High Growth Revenue: Insufficient data to determine if SMSPHARMA's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SMSPHARMA's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.